Table 1.
Patient and Study Eye Characteristics by Treatment Outcome at 3, 6, and 12 Months
| Characteristics | 3-mo Outcome (n = 166) |
6-mo outcome (n = 168) |
12-mo outcome (n = 149) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| Stable/Worse VA | Improved VA | P | Stable/Worse VA | Improved VA | P | Stable/Worse VA | Improved VA | P | |
| Age, median (p25, p75) | 81 (76, 85) | 78 (73, 82) | 0.16 | 81 (77, 85) | 77 (72, 82) | 0.03 | 81 (77, 85) | 79 (73, 81) | 0.03 |
| Sex | |||||||||
| Male | 45 (64) | 25 (36) | 0.07 | 44 (37) | 26 (53) | 0.06 | 41 (36) | 18 (50) | 0.14 |
| Female | 74 (77) | 22 (23) | 75 (63) | 23 (47) | 72 (64) | 18 (50) | |||
| Smoking | |||||||||
| Nonsmoker | 49 (79) | 13 (21) | 0.09 | 47 (43) | 16 (35) | 0.36 | 41 (38) | 16 (47) | 0.37 |
| Past/present smoker | 61 (66) | 31 (34) | 63 (57) | 30 (65) | 66 (62) | 18 (53) | |||
| APOE genotypes | |||||||||
| ε2/ε2; ε2/ε3 | 25 (83) | 5 (17) | 0.06 | 26 (22) | 4 (8) | 0.11 | 22 (19) | 4 (11) | 0.25 |
| ε3/ε3 | 79 (72) | 30 (28) | 75 (63) | 36 (74) | 76 (67) | 23 (64) | |||
| ε3/ε4; ε4/ε4 | 15 (55) | 12 (45) | 18 (15) | 9 (18) | 15 (13) | 9 (25) | |||
| APOE alleles (ε2 vs. ε4) | |||||||||
| ε2 | 25 (83) | 5 (17) | 0.02 | 26 (87) | 4 (13) | 0.07 | 22 (85) | 4 (15) | 0.06 |
| ε4 | 15 (55) | 12 (45) | 18 (67) | 9 (33) | 15 (62) | 9 (38) | |||
| Baseline logMAR VA median (p25, p75)* | 0.60 (0.40, 0.90) | 0.70 (0.48, 1.00) | 0.60 (0.40, 0.78) | 0.78 (0.48, 1.00) | 0.02 | 0.60 (0.48, 0.78) | 0.74 (0.50, 1.00) | 0.01 | |
| Time delay: symptoms to treatment, wk | |||||||||
| Lowest tertile (<7) | 34 (64) | 19 (36) | 0.22 | 34 (62) | 20 (38) | 0.32 | 34 (76) | 11 (24) | 0.72 |
| Middle tertile (7–21) | 36 (80) | 9 (20) | 32 (71) | 13 (29) | 35 (80) | 9 (20) | |||
| Highest tertile (>21) | 32 (70) | 14 (30) | 36 (77) | 11 (23) | 31 (72) | 12 (18) | |||
| Time delay: diagnosis of CNV to treatment, wk | |||||||||
| Lowest tertile (<1) | 51 (69) | 23 (31) | 0.21 | 55 (73) | 20 (27) | 0.33 | 50 (78) | 14 (22) | 0.02 |
| Middle tertile (1–3) | 31 (67) | 15 (33) | 29 (63) | 17 (37) | 27 (61) | 17 (39) | |||
| Highest tertile (>3) | 37 (82) | 8 (18) | 35 (76) | 11 (24) | 36 (70) | 5 (30) | |||
| CNV lesion type | |||||||||
| Predominantly classic | 29 (66) | 15 (34) | 0.30 | 32 (73) | 12 (27) | 0.78 | 26 (65) | 14 (35) | 0.07 |
| Non-predominantly classic† | 89 (74) | 31 (16) | 86 (70) | 36 (30) | 86 (80) | 22 (20) | |||
| Total CNV lesion size | |||||||||
| ≤2 DA | 68 (67) | 33 (33) | 0.07 | 71 (69) | 32 (31) | 0.27 | 67 (74) | 24 (26) | 0.47 |
| >2 DA | 43 (81) | 10 (19) | 41 (77) | 12 (23) | 38 (79) | 10 (21) | |||
| Number of treatments | |||||||||
| ≤3 | 49 | 119 | — | 58 (64) | 23 (36) | 0.94 | 33 (85) | 6 (15) | 0.22 |
| >3 | — | — | — | 59 (71) | 24 (29) | 78 (75) | 26 (25) | ||
n (%) for categorical variables; median (p25, p75) for continuous variables. Percentages may not total 100 due to rounding. Apo ε2 is constituted by the ε2/ε2 and ε2/ε3 genotypes; Apo ε4 is constituted by the ε3/ε4 and ε4/ε4 genotypes.
*
VA worsens as logMAR value increases.
†
Includes minimally classic, occult, retinal angiomatous proliferation, fibrovascular pigment epithelial detachment.